Bristol Myers Squibb Reports Phase 3 subgroup analysis Data for Selpercatinib in Chronic hand eczema

Bristol Myers Squibb today announced Phase 3 subgroup analysis results for Selpercatinib in patients with Chronic hand eczema. The study demonstrated that Selpercatinib demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Chronic hand eczema and support the continued development of Selpercatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Selpercatinib was consistent with previous observations, with no new safety signals identified.